Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 09, 2020 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Establishes Research Collaboration with University of Tennessee Health Science Center to Investigate Small Molecule Rose Bengal Disodium for Antibiotic Resistance

KNOXVILLE, TN, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that the Company has initiated a new sponsored research program with Michio Kurosu, PhD, Professor,...
June 09, 2020 09:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Expands Global Patent Portfolio to India for Cancer Combination Therapy

2020 India patent follows 2018 India patent that protects Provectus’ proprietary API manufacturing processProvectus further expands cancer combination therapy IP protection by filing new USPTO patent...
April 29, 2020 16:30 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Announces Acceptance of PV-10® Liver Cancer Abstracts at American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program

KNOXVILLE, TN, April 29, 2020 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today is pleased to announce that abstracts about and data from our clinical trials of investigational autolytic cancer...
November 21, 2019 10:19 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Announces Presentation of Initial Results from Phase 1B Trial of PV-10® in Combination with KEYTRUDA® for Treatment of Checkpoint-Refractory Advanced Melanoma at SMR 2019 Congress

First 10 checkpoint-refractory melanoma patients treatedEstablished safety profiles of PV-10 and KEYTRUDA were maintained20% ORR and 40% DCR (RECIST 1.1)Changes in immune system activation biomarkers...
April 17, 2019 16:05 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Acceptances of PV-10 Poster Presentations at American Society of Clinical Oncology (ASCO) Annual Meeting

Metastatic neuroendocrine tumors; Advanced cutaneous melanomaIntratumoral administration of PV-10 to visceral and superficial disease locationsSingle-agent and combination therapy treatment settings ...
March 25, 2019 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Appoints Heather Raines, CPA as Chief Financial Officer

KNOXVILLE, TN, March 25, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced the appointment of Heather Raines as the Company’s Chief Financial Officer (CFO). Mrs. Raines had previously...
March 21, 2019 08:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Provides Update on Metastatic Uveal Melanoma Clinical Development Program for Investigational Drug PV-10

KNOXVILLE, TN, March 21, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updates on the Company's metastatic uveal melanoma drug development program for its lead investigational...
February 12, 2019 07:30 ET | Source: Provectus Biopharmaceuticals Inc.

PROVECTUS ANNOUNCES GRANT OF ORPHAN DRUG DESIGNATION IN U.S. TO PV-10 FOR TREATMENT OF OCULAR MELANOMA

KNOXVILLE, TN, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that orphan drug designation (ODD) status was granted by the U.S. Food and Drug Administration (FDA) to small...
December 06, 2018 08:30 ET | Source: Provectus Biopharmaceuticals Inc.

PROVECTUS BIOPHARMACEUTICALS PROVIDES UPDATE ON MELANOMA CLINICAL DEVELOPMENT PROGRAM FOR INVESTIGATIONAL DRUG PV-10

Lesion-level response data from main cohort of advanced melanoma patients naïve to immune checkpoint inhibition in Phase 1b/2 combination study of PV-10 and KEYTRUDA® (pembrolizumab) presented at...
November 12, 2018 09:00 ET | Source: Provectus Biopharmaceuticals Inc.

University of Tennessee Haslam College of Business Recognizes Provectus Biopharmaceuticals Chairman Ed Pershing as 2018 Outstanding Entrepreneur

KNOXVILLE, TN, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today announced that Ed Pershing, CPA, the Chairman of the Company’s board of directors, was recognized by the Haslam...